Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | MARS1 | P56192 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27282906 | 0.88 | JAK2 (0.37) | CNR1NPC1JAK2ALPLMARS1 | |
| SCHEMBL27282894 | 0.84 | CNR1 (0.36) | CNR1CNR2DGAT1 | |
| SCHEMBL27082828 | 0.81 | ROCK2 (0.39) | CNR1NPC1JAK2CNR2MARS1 | |
| SCHEMBL27282909 | 0.77 | JAK2 (0.44) | CNR1JAK2JAK1TYK2 | |
| SCHEMBL27282908 | 0.77 | JAK2 (0.42) | CNR1NPC1JAK2JAK1TYK2 | |
| SCHEMBL27282911 | 0.77 | JAK2 (0.37) | CNR1NPC1JAK2ALPLJAK1 | |
| SCHEMBL27282921 | 0.75 | NPC1 (0.35) | NPC1JAK2DGAT1 | |
| SCHEMBL27282733 | 0.74 | JAK2 (0.45) | JAK2JAK1TYK2 | |
| SCHEMBL27282887 | 0.71 | KDM4E (0.37) | CNR1CNR2 | |
| SCHEMBL27082552 | 0.69 | JAK2 (0.53) | JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-07-04 | — | — | US | disclosed |
| CN-117157289-A | Substituted pyrrolecarboxamides, process for their preparation and their use as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDC7, CDK7, CDK17 | CNR1 2599/4885NPC1 3336/4885JAK2 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.